Social media

On 4 – 6 November in Boston, MA, ICON will be sponsoring the World Drug Safety Congress. This leading event brings together more than 2,000 drug safety professionals from across pharma, biotech, regulatory authorities, a...

Every successful clinical trial begins long before the first patient visit. Site selection and activation play a critical role in ensuring that trials start efficiently and deliver meaningful outcomes. Our latest blog e...

Every successful clinical trial begins long before the first patient visit. Site selection and activation play a critical role in ensuring that trials start efficiently and deliver meaningful outcomes. Our latest blog e...

Meet us at #ObesityWeek, Nov 4–7 at booth \#520 to explore how our comprehensive approach to obesity asset development can accelerate your program. From imaging and diagnostics to patient adjudication, device experience,...

Although biosimilars play an important role in improving cancer treatment accessibility, many patients and providers hold misconceptions or doubts about them. Learn how oncology biosimilar developers can encourage uptake...

Although biosimilars play an important role in improving cancer treatment accessibility, many patients and providers hold misconceptions or doubts about them. Learn how oncology biosimilar developers can encourage uptake...

Technology is the backbone of modern risk-based quality monitoring. ICON’s latest blog explores how central monitoring, predictive analytics and system-agnostic platforms enable earlier risk detection and more efficient ...

Technology is the backbone of modern risk-based quality monitoring. ICON’s latest blog explores how central monitoring, predictive analytics and system-agnostic platforms enable earlier risk detection and more efficient ...

Attending #ACR25? Meet ICON experts at booth \#1501 to learn how our tailored strategies, delivered with flexibility and deep therapeutic expertise, can help you drive success in your clinical trial.  https://lnkd.in/eHf...

Historically, high development costs and complex approval processes have been an impediment to #biosimilar development. There is an urgent need to promote changes in how regulators assess biosimilars, as well as to ide...

Historically, high development costs and complex approval processes have been an impediment to biosimilar development. There is an urgent need to promote changes in how regulators assess biosimilars, as well as to identi...

Proven success in early phase obesity studies. See how ICON streamlined an early phase obesity study with tailored recruitment, participant-centric support, and operational excellence to reduce dropout rates and ensure c...